Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Initial results from the Phase 1 trial for the rVSV ZEBOC candidate Ebola vaccine have now been published. The trial found that the candidate vaccine had no serious side effects although some volunteers experienced fever for the first few days after vaccination, and some developed transient pain and/or swelling of their joints. The candidate vaccine was able to raise antibody responses that neutralized Ebola-like virus particles in the laboratory.